VAP(R) Cholesterol Test helps physicians identify emerging risk factors better than standard cholesterol test and traditional risk factors, study shows
BIRMINGHAM, Ala., Jan. 30 /PRNewswire/ -- Traditional risk factors such as age, standard cholesterol levels and blood pressure do a poor job of predicting heart disease risk in younger, healthy adults with a family history of early heart disease. That's according to a recent study published in Clinical Cardiology, which revealed that "emerging risk factors," including detailed cholesterol measurements such as HDL(2) and remnant lipoprotein particles, play a much greater role in determining heart disease risk than previously thought.
The study is titled Prevalence of Emerging Cardiovascular Risk Factors in Younger Individuals with a Family History of Premature Coronary Heart Disease and Low Framingham Risk Score. It is the latest in a series of clinical studies showing that the traditional Framingham risk score doesn't always do a good job of estimating that risk, especially among people in their mid-30s to early 60s.
Measurement of emerging clinical and lipid risk factors in the study was done with the VAP(R) (Vertical Auto Profile) Cholesterol Test from Atherotech, Inc. Physicians are increasingly using such detailed cholesterol testing to more accurately identify their parents' true risk of heart disease, allowing for treatment and lifestyle changes that can decrease the risk of a heart attack or stroke.
Atherotech Chief Medical Officer James Ehrlich, M.D., said the study is consistent with a growing body of research revealing how poorly the office-based exam using Framingham analysis and traditional cholesterol testing performs in identifying true cardiac risk.
"Clearly it is time for physicians to take a much more sophisticated and individualized approach to cardiac risk assessment," said Ehrlich, "wh
|SOURCE Atherotech, Inc.|
Copyright©2009 PR Newswire.
All rights reserved